Alzheimer's disease

Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Investors Business Daily
Alzheimer's disease
drug development
Biogen
Eisai
Flag link:
Research Roundup: A New Protein Linked to Alzheimer’s and Other Highlights
Research Roundup: A New Protein Linked to Alzheimer’s and Other Highlights
BioSpace
R&D
Alzheimer's disease
genetic translation
Flag link:
A Missed Alzheimer’s Opportunity? Not So Much
A Missed Alzheimer’s Opportunity? Not So Much
In the Pipeline
Pfizer
Enbrel
Alzheimer's disease
social media
clinical trials
journalism
Flag link:
Pfizer had clues its blockbuster drug could prevent Alzheimer’s. Why didn’t it tell the world?
Pfizer had clues its blockbuster drug could prevent Alzheimer’s. Why didn’t it tell the world?
Washington Post, DC
Pfizer
Enbrel
Alzheimer's disease
Flag link:
Could This Blood Test Revolutionise How Dementia and Other Neurodegenerative Diseases Are Diagnosed?
Could This Blood Test Revolutionise How Dementia and Other Neurodegenerative Diseases Are Diagnosed?
Forbes
Alzheimer's disease
dementia
neurodegenerative disease
Enya Labs
diagnostics
Flag link:
T3D Therapeutics Receives $9 Million NIH Grant to Advance Alzheimer's Clinical Trial
T3D Therapeutics Receives $9 Million NIH Grant to Advance Alzheimer's Clinical Trial
BioSpace
T3D Therapeutics
NIH
Alzheimer's disease
clinical trials
T3D-959
Flag link:
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Endpoints
Alzheimer's disease
drug development
aducanumab
Biogen
Eisai
BAN2401
Merck
Eli Lilly
AstraZeneca
Flag link:
Merck Ready to Submit Belsomra to FDA for Alzheimer's Insomnia
Merck Ready to Submit Belsomra to FDA for Alzheimer's Insomnia
BioSpace
Merck
Belsomra
insomnia
Alzheimer's disease
Flag link:
Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs
Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs
BioSpace
Eisai
Biogen
Alzheimer's disease
R&D
aducanumab
BAN2401
Flag link:
After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
NPR
Alzheimer's disease
R&D
drug development
beta amyloid
Biogen
Eisai
aducanumab
Flag link:
Biogen says it will not give up on Alzheimer’s after failed trials
Biogen says it will not give up on Alzheimer’s after failed trials
Marketwatch
Biogen
drug development
Alzheimer's disease
Flag link:
Biogen cans plan to test aducanumab in Alzheimer's prevention
Biogen cans plan to test aducanumab in Alzheimer's prevention
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
cilnical trials
Flag link:
What does the past generation of failure in Alzheimer’s R&D look like in one slide?
What does the past generation of failure in Alzheimer’s R&D look like in one slide?
Endpoints
R&D
Alzheimer's disease
amyloid beta
Eli Lilly
Pfizer
JNJ
Flag link:
EIP bags cash to trial ex-Vertex drug in dementia, Huntington's
EIP bags cash to trial ex-Vertex drug in dementia, Huntington's
Fierce Biotech
EIP Pharma
Alzheimer's disease
dementia
Huntington's disease
Flag link:
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
CP Wire
Cortexyme
IPOs
COR388
Alzheimer's disease
Flag link:
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
Cortexyme
IPOs
COR388
Alzheimer's disease
Flag link:
Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma
Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma
Fierce Biotech
M3 Biotechnology
rebranding
Athira Pharma
Alzheimer's disease
Flag link:
Should Biogen Investors Be Extra Nervous Right Now?
Should Biogen Investors Be Extra Nervous Right Now?
Motley Fool
Biogen
Alzheimer's disease
ICER
investors
Spinraza
Flag link:
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Alzheimer's disease
Biogen
aducanumab
Otsuka
Axsome Therapeutics
Amgen
Novartis
Avanir
AVP-786
AXS-05
AMG520
Flag link:
What Are Biopharma Leaders Focused on?
What Are Biopharma Leaders Focused on?
BioSpace
drug pricing
regulatory
innovation
value-based drug pricing
government
Alzheimer's disease
drug manufacturing
Flag link:

Pages